Diab spot is a non-invasive test to identify people at risk for diabetes or pre-diabetes without overnight fasting, a blood draw, or waiting for a lab result.
- More accurate than FPG or HbA1c
- Easy to use
- Fast (within 1 minute)
- Cost-effective
The AGE Reader provides an immediate cardiovascular risk prediction in major chronic diseases such as diabetes, renal failure and cardiovascular disease.
- Clinically validated
- Non-invasive point-of-care test
- Safe and convenient
- Cost-effective
Find a distributor in your country. If your country is not listed, please contact DiagnOptics for your enquiries: sales@diagnoptics.com
DiagnOptics and PATH partner on project on diabetes screening in India
Groningen, the Netherlands – February 6, 2012 DiagnOptics and PATH partner on a clinical study in which the performance of point-of-care techno......
» read moreThe AGE Reader and Diab-spot have received approval in a number of countries. Please check with the distributor in your country or DiagnOptics what the regulatory approval status is in your country. US Caution: Federal law restricts the AGE Reader and Diab-spot system to investigational use only. Commercial distribution has not been granted by the US FDA. Please see the AGE Reader and Diab-spot user manuals for descriptions of all relevant warnings, cautions, contraindications and safety information.
Find information about DiagnOptics.
Find information about DiagnOptics' products and Advanced Glycation Endproducts.
Find information about Advanced Glycation Endproducts, the AGE measurement and the clinical validation.
